P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 23.5 CNY 0.34% Market Closed
Market Cap: 12.8B CNY

Porton Pharma Solutions Ltd's latest stock split occurred on Sep 29, 2015

The company executed a 15-for-10 stock split, meaning that for every 10 shares held, investors received 15 new shares.

Before the split, Porton Pharma Solutions Ltd traded at 32.9 per share. Afterward, the share price was about 21.1994.

The adjusted shares began trading on Sep 29, 2015. This was Porton Pharma Solutions Ltd's 2nd stock split, following the previous one in Mar 26, 2015.

Last Splits:
Sep 29, 2015
15-for-10
Mar 26, 2015
25-for-10
Pre-Split Price
20.7577 32.9
Post-Split Price
21.1994
Before
After
Last Splits:
Sep 29, 2015
15-for-10
Mar 26, 2015
25-for-10

Porton Pharma Solutions Ltd
Stock Splits History

Porton Pharma Solutions Ltd Stock Splits Timeline
Sep 29, 2015
Sep 29, 2015
Split 15-for-10
x1.5
Pre-Split Price
20.7577 32.9
Post-Split Price
21.1994
Before
After
Mar 26, 2015
Mar 26, 2015
Split 25-for-10
x2.5
Pre-Split Price
36.7543 145.7502
Post-Split Price
40.4303
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.22 45.22 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
61.4 61.4 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Porton Pharma Solutions Ltd
Glance View

Market Cap
12.8B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd., rooted in the vibrant landscape of China's pharmaceutical sector, has strategically navigated its way to becoming a pivotal player in the global Contract Development and Manufacturing Organization (CDMO) industry. Founded in 2005, the company harnesses the intricate synergy between chemistry and biology to drive its core operations. Porton specializes in providing a comprehensive suite of services ranging from early drug development to commercial-scale manufacturing. The company's business model thrives on forming collaborative partnerships with global pharmaceutical and biotechnology firms, offering customized solutions tailored to specific drug production needs. By acting as an extension of its clients' research and development teams, Porton effectively reduces the time and investment required for its clients to bring new drugs to market, catalyzing its own revenue through long-standing service agreements. The essence of Porton’s value proposition lies in its robust technological capabilities and commitment to compliance with international quality standards, which ensures client trust and repeat business. Porton's facilities are outfitted with cutting-edge technologies that support complex chemical synthesis and advanced bioprocessing, allowing them to expertly handle high-potency and complex molecules. Additionally, the company leverages its strategic geographic advantage in China to offer competitive pricing while maintaining quality excellence, a crucial factor in contracting agreements. Through continuous investments in research and development, and a commitment to operational efficiency, Porton Pharma Solutions Ltd. not only accelerates its clients' drug development timelines but also enhances its own profitability, positioning itself as a leader in the evolving CDMO landscape.

Intrinsic Value
18.39 CNY
Overvaluation 22%
Intrinsic Value
Price
P
Back to Top